|4Jun 26, 8:23 AM ET

RXi Pharmaceuticals Corp 4

4 · RXi Pharmaceuticals Corp · Filed Jun 26, 2017

Insider Transaction Report

Form 4
Period: 2017-06-23
Dispersyn Gerrit
Chief Development Officer
Transactions
  • Purchase

    Common stock, $0.0001 par value

    2017-06-23$0.62/sh+3,500$2,1703,500 total

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION